Former interim CEO John Journee has been appointed as the retailer’s next chair, replacing Joan Withers, who says the board has been through ‘crucible of pain’.
The company’s share price has more than halved from the peak it hit during the 2020 equity market bull run.
The pharmaceutical company remains confident in its own business model, as it mulls how much to pay out in dividends this year.
Board ditches interim dividend as half-year revenue and profit slump.
The company’s operating earnings rose 12% in the past six months.
Net loss of $1.2m in the year ended September after multiple weather events, compared with $18.9m profit last year.
Telco and Positioning segments suffer but products for Space & Defence and AI industries find favour.
‘We have a strong cash balance ... that gives us options,’ CEO says.
Insurer reports overall loss in year ended September, while no dividend will be paid.
Although one market source suggests the terms were ‘stretchy’ at best.